Johnson & Johnson (JNJ) Announces the FDA Approval of TECVAYLI® plus DARZALEX FASPRO®

Johnson & Johnson (NYSE:JNJ) is one of the best stocks that will always grow. Johnson & Johnson (NYSE:JNJ) announced on March 5 that the U.S. Food and Drug Administration (FDA) granted approval for TECVAYLI® plus DARZALEX FASPRO® for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. Management reported that the approval offers a potential new standard of care as early ...